Biohit: New review combines key products into a care pathway
Summary
- Biohit announced a new scientific review outlining a two-step strategy for gastric cancer prevention using GastroPanel and Acetium products, enhancing their sales and marketing efforts.
- The review integrates Acetium, previously less commercially significant, with the company's main product, GastroPanel, strengthening its scientific basis.
- The strategy involves identifying risk groups with GastroPanel and using Acetium to reduce cancer risk, aiming to convince healthcare professionals of its preventive benefits.
- The "screen and prevent" strategy could enhance the commercialization of Acetium by linking it to GastroPanel's test results, supporting cross-selling to at-risk groups.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 9/10/2026 at 7:10 am EEST.
Biohit announced on Wednesday a new scientific review presenting the company's two-step strategy for gastric cancer prevention, which relies on the GastroPanel and Acetium products. We find the publication useful as support material for sales and marketing efforts. In particular, it strengthens the scientific basis of Acetium by integrating the product, which previously played a smaller commercial role, into the use of the company's spearhead product. The news is an expected step forward in packaging the clinical evidence for the products and does not cause any changes to our forecasts.
Study combines the company's key products into one package
The concept presented in the review is based on identifying risk groups with the GastroPanel blood test, after which Acetium capsules are used to decrease the exposure to cancer-causing acetaldehyde in patients with acid-free stomachs. Although this is a review article rather than new clinical data, it logically combines the company's two key innovations into a care pathway. We estimate that such clear clinical protocols are important as the company seeks to convince healthcare professionals and decision-makers of the benefits of wider product use as part of preventive healthcare.
Support particularly for the commercialization of Acetium
Our previous assessment concluded that Biohit’s long-term strategic growth relies heavily on the GastroPanel product family, while Acetium products aimed at the consumer market have played a significantly smaller commercial role for the company. The newly introduced "screen and prevent" strategy links the use of Acetium more closely to objective test results produced by the GastroPanel and can support cross-selling capsules to at-risk groups.